Abstract
L1, a neuronal cell adhesion receptor of the immunoglobulin-like protein family is expressed in invading colorectal cancer (CRC) cells as a target gene of Wnt/β-catenin signaling. Overexpression of L1 in CRC cells enhances cell motility and proliferation, and confers liver metastasis. We recently identified ezrin and the IκB-NF-κB pathway as essential for the biological properties conferred by L1 in CRC cells. Here, we studied the underlying molecular mechanisms and found that L1 enhances ezrin phosphorylation, via Rho-associated protein kinase (ROCK), and is required for L1–ezrin co-localization at the juxtamembrane domain and for enhancing cell motility. Global transcriptomes from L1-expressing CRC cells were compared with transcriptomes from the same cells expressing small hairpin RNA (shRNA) to ezrin. Among the genes whose expression was elevated by L1 and ezrin we identified insulin-like growth factor-binding protein 2 (IGFBP-2) and showed that its increased expression is mediated by an NF-κB-mediated transactivation of the IGFBP-2 gene promoter. Expression of a constitutively activated mutant ezrin (Ezrin567D) could also increase IGFBP-2 levels in CRC cells. Overexpression of IGFBP-2 in CRC cells lacking L1-enhanced cell proliferation (in the absence of serum), cell motility, tumorigenesis and induced liver metastasis, similar to L1 overexpression. Suppression of endogenous IGFBP-2 in L1-transfected cells inhibited these properties conferred by L1. We detected IGFBP-2 in a unique organization at the bottom of human colonic crypts in normal mucosa and at increased levels throughout human CRC tissue samples co-localizing with the phosphorylated p65 subunit of NF-κB. Finally, we found that IGFBP-2 and L1 can form a molecular complex suggesting that L1-mediated signaling by the L1–ezrin–NF-κB pathway, that induces IGFBP-2 expression, has an important role in CRC progression.
Similar content being viewed by others
References
Clevers H . Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469–480.
Polakis P . The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45–51.
Brümmendorf T, Kenwrick S, Rathjen FG . Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations. Curr Opin Neurobiol 1998; 8: 87–97.
Hortsch M . Structural and functional evolution of the L1 family: are four adhesion molecules better than one? Mol Cell Neurosci 2000; 15: 1–10.
Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze’ev A . L1-CAM in cancerous tissues. Exp Opin Biol Ther 2008; 8: 1749–1757.
Conacci-Sorrell M, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze’ev A . Nr-CAM is a target gene of the β-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16: 2058–2072.
Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T et al. L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168: 633–642.
Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 2007; 67: 7703–7712.
Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze’ev A . Nuclear factor-κB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 2010; 15: 2135–2143.
Bretscher A, Edwards K, Fehon RG . ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3: 586–599.
Fiévet B, Louvard D, Arpin M . ERM proteins in epithelial cell organization and functions. Biochim Biophys Acta 2007; 1773: 653–660.
Gavert N, Vivanti A, Hazin J, Brabletz T, Ben-Ze’ev A . L1-mediated colon cancer cell metastasis does not require changes in EMT and cancer stem cell markers. Mol Cancer Res 2011; 9: 14–24.
Gautreau A, Louvard D, Arpin M . Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol 2002; 10: 193–203.
Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 1998; 140: 647–657.
Ren L, Hong SH, Cassavaugh J, Osborne T, Chou AJ, Kim SY et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 2009; 28: 792–802.
Mishra L, Bass B, Ooi BS, Sidawy A, Korman L . Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res 1998; 8: 473–479.
Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915–928.
Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012; 19: 269–281.
Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y et al. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. J Biol Chem 2009; 284: 27456–27466.
Firth SM, Baxter RC . Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824–854.
Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW . Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32: 859–868.
Wang GK, Hu L, Fuller GN, Zhang W . An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin α5 is essential for IGFBP2-induced cell mobility. J Biol Chem 2006; 281: 14085–14091.
Mendes KN, Wang GK, Fuller GN, Zhang W . JNK mediates insulin-like growth factor binding protein 2/integrin α5-dependent glioma cell migration. Int J Oncol 2010; 37: 143–153.
Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE et al. PAPA-1 is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol 2009; 23: 169–175.
Busund LT, Ow KT, Russell P, Crowe PJ, Yang JL . Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 2004; 444: 142–148.
Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG . Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76: 1031–1035.
Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, Grote EH et al. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 2001; 142: 1652–1658.
Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001; 61: 8601–8610.
Karasik A, Menczer J, Pariente C, Kanety H . Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994; 78: 271–276.
El Atiq F, Garrouste F, Remacle BM, Sastre B, Pommier G . Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994; 57: 491–497.
Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592–1600.
Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC et al. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab 2010; 95: 1717–1725.
Renehan AG, Painter JE, O’Halloran D, Atkin WS, Potten CS, O’Dwyer ST et al. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 2000; 85: 3402–3408.
Png KJ, Halberg N, Yoshida M, Tavazoie SF . A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2011; 481: 190–194.
Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L et al. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci USA 2009; 106: 16675–16679.
Pollak M . The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012; 18: 40–50.
So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008; 14: 6944–6954.
Hlavin ML, Lemmon V . Molecular structure and functional testing of human L1CAM: an interspecies comparison. Genomics 1991; 11: 416–423.
Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C . The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. J Biol Chem 2006; 281: 39607–39619.
Langsrud Ø, Jørgensen K, Ragni Ofstad R, Næs T . Analyzing designed experiments with multiple responses. J Appl Stat 2007; 34: 1275–1296.
Acknowledgements
We thank Drs M Arpin, M Pollak, W Zhang and V Lemmon for providing reagents. This study was supported by grants from the Israel Science Foundation (ISF) and from Israel Cancer Research Fund (ICRF). AB-Z is the incumbent of the Lunenfeld-Kunin Professorial chair of genetics.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ben-Shmuel, A., Shvab, A., Gavert, N. et al. Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression. Oncogene 32, 3220–3230 (2013). https://doi.org/10.1038/onc.2012.340
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2012.340
- Springer Nature Limited
Keywords
This article is cited by
-
WNT/beta-catenin signalling interrupts a senescence-induction cascade in human mesenchymal stem cells that restricts their expansion
Cellular and Molecular Life Sciences (2022)
-
Anticancer properties of dried-pericarp water extracts of Camellia japonica L. fermented with Aspergillus oryzae through regulation of IGFBP-2/mTOR pathway
Scientific Reports (2021)
-
IGFBP2: integrative hub of developmental and oncogenic signaling network
Oncogene (2020)
-
The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer
Oncogene (2019)
-
MicroRNA-105 is involved in TNF-α-related tumor microenvironment enhanced colorectal cancer progression
Cell Death & Disease (2017)